Results 31 to 40 of about 41,395 (219)

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts

Frontiers in Immunology, 2023
Background Chimeric antigen receptor (CAR)-T cell therapy has established itself as a potent therapeutic option for certain patients with relapsed/refractory (R/R) hematologic malignancies.
F. Nasiri, Pooria Safarzadeh Kozani, F. Rahbarizadeh   +2 more
semanticscholar   +1 more source

Structural Classification of CDR-H3 in Single-Domain VHH Antibodies.

Methods in molecular biology, 2023
The immune systems protect vertebrates from foreign molecules or antigens, and antibodies are important mediators of this system. The sequences and structural features of antibodies vary depending on species.
Daisuke Kuroda, K. Tsumoto
semanticscholar   +1 more source

AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study

Frontiers in Molecular Biosciences, 2023
Introduction: In this study, we demonstrate the feasibility of yeast surface display (YSD) and nextgeneration sequencing (NGS) in combination with artificial intelligence and machine learning methods (AI/ML) for the identification of de novo humanized ...
Paul Arras, Han Byul Yoo, Lukas Pekar, Thomas Clarke, Lukas Friedrich, Christian Schröter, J. Schanz, Jason Tonillo, Vanessa Siegmund, Achim Doerner, S. Krah, Enrico Guarnera, Stefan Zielonka, Andreas Evers   +13 more
semanticscholar   +1 more source

Intracellular VHHs to monitor and modulate GPCR signaling

Frontiers in Endocrinology, 2022
Single-domain antibody fragments, also known as VHHs or nanobodies, have opened promising avenues in therapeutics and in exploration of intracellular processes. Because of their unique structural properties, they can reach cryptic regions in their cognate antigen.
Pauline Raynaud, Camille Gauthier, Vinesh Jugnarain, Frédéric Jean-Alphonse, Frédéric Jean-Alphonse, Eric Reiter, Eric Reiter, Gilles Bruneau, Pascale Crépieux, Pascale Crépieux   +9 more
openaire   +5 more sources

Peptide Linker Affecting the Activity Retention Rate of VHH in Immunosorbents

Biomolecules, 2020
VHH-based immunosorbents are an emerging and promising tool for the removal of toxic substances from plasma. However, the small size of VHHs is a double-edged sword, bringing both benefits and drawbacks to the immunosorbent.
Da Li, Jun Ren, Fangling Ji, Qiang Peng, Hu Teng, Lingyun Jia   +5 more
doaj   +1 more source

Nanobodies: their potential for applications in biotechnology, diagnosis and antiviral properties in Africa; focus on application in agriculture

Biotechnology & Biotechnological Equipment, 2021
Antibodies are key elements in routine immunological tests, having a long history in detection of plant pathogens due to their specificity, reliability and fast performance.
Faith Njeri Njeru, Paul Mbogo Kusolwa
doaj   +1 more source

Renoprotective Effect of the Recombinant Anti-IL-6R Fusion Proteins by Inhibiting JAK2/STAT3 Signaling Pathway in Diabetic Nephropathy

Frontiers in Pharmacology, 2021
Diabetic nephropathy the main reason for end stage renal disease is a common microvascular complication in patients with type 1 and type 2 diabetes. The interleukin-6 (IL-6), acting as a pleiotropic cytokine, play key roles in main autoimmune disorders ...
Nanwen Zhang, Nanwen Zhang, Qingmei Zheng, Yaduan Wang, Juan Lin, He Wang, Rui Liu, Mengru Yan, Xiaofeng Chen, Juhua Yang, Juhua Yang, Xiaole Chen, Xiaole Chen   +12 more
doaj   +1 more source

A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization

mAbs, 2023
In this study, we generated a novel library approach for high throughput de novo identification of humanized single-domain antibodies following camelid immunization. To achieve this, VHH-derived complementarity-determining regions-3 (CDR3s) obtained from
Paul Arras, Han Byul Yoo, Lukas Pekar, C. Schröter, Thomas Clarke, S. Krah, Daniel Klewinghaus, Vanessa Siegmund, Andreas Evers, Stefan Zielonka   +9 more
semanticscholar   +1 more source

Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities

mAbs, 2022
Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the ...
Desislava Yanakieva, Lukas Pekar, Andreas Evers, Markus Fleischer, Stephan Keller, Dirk Mueller-Pompalla, Lars Toleikis, Harald Kolmar, Stefan Zielonka, Simon Krah   +9 more
doaj   +1 more source

Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration.

Molecular Immunology, 2023
The bispecific antibody gefurulimab (also known as ALXN1720) was developed to provide patients with a subcutaneous treatment option for chronic disorders involving activation of the terminal complement pathway.
S. Jindal, Dennis Vestergaard Pedersen, Nimish Gera, J. Chandler, Rekha Patel, Alyssa Neill, Josh Cone, Yuchun Zhang, Chao-Xing Yuan, Ellen E. Millman, Dan Carlin, B. Puffer, D. Sheridan, G. R. Andersen, Paul Tamburini   +14 more
semanticscholar   +1 more source